CHICAGO (Reuters) - The U.S. government has awarded Novavax Inc (O:NVAX) $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.
stock + 27% at 102.
you have sold...